Thu, Dec 18, 2014, 3:03 AM EST - U.S. Markets open in 6 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

pSivida Corp. Message Board

  • mickmack50 mickmack50 Dec 6, 2013 9:09 AM Flag

    Lori Freedman At LD Micro

    For all serious PSDV investors, you might catch the webcast (available at PSDV website) that Lori presented yesterday. She was very dynamic in her presentation. Her delivery was very enthusiastic and upbeat. I'm a big fan of Paul Ashton, but Lori's style was very well received. Though Medidur for Uveitis is our "bedrock" NDA, she did spend ample time explaining Tethadur and it's massive potential. This is the first presentation that I've heard of hers, I think she's off to a great start.....and she just make get the job. Plus, she mentioned pre-clinical data of Tethadur soon. That's what I want for Christmas.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Pre-clinical data on Tethadur is a big deal, because if it's good news {which it more than likely will be}, then it'll be heading to the clinic after contracts are ironed out. Possible up front payment, etc..... debating whether to buy more shares with just this news alone coming. ...

    • trollen32@sbcglobal.net trollen32 Dec 6, 2013 9:14 AM Flag

      Tethadur is where I'm at on this, not that all the other developments are chopped Liver,........Just feel that this is the booster rocket we've been waiting to get us off the pad..............Luck tro

      • 1 Reply to trollen32
      • Tro, I'm obviously with you. However, the market gives the Tethadur platform squat. It's going to take real data and a license deal to validate it. The tech agreements are phase 1, a license deal with big pharma will take us to a much higher and rightly deserved level. The clock is ticking. Which big pharma gets the platform first, and are they going to write in purchase option? Paul won't give it away you can be sure.

 
PSDV
4.10+0.01(+0.24%)Dec 17 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Rite Aid Corporation
NYSEWed, Dec 17, 2014 4:01 PM EST
NPS Pharmaceuticals, Inc.
NasdaqGSWed, Dec 17, 2014 4:00 PM EST